Literature DB >> 19410458

Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.

Cuihua Wang1, Sofia Barluenga, Girish K Koripelly, Jean-Gonzague Fontaine, Ruihong Chen, Jin-Chen Yu, Xiaodong Shen, John C Chabala, James V Heck, Allan Rubenstein, Nicolas Winssinger.   

Abstract

Pochoximes are potent inhibitors of heat shock protein 90 (HSP90) based on the radicicol pharmacophores. Herein we present a pharmacokinetics and pharmacodynamics evaluation of this compound series as well as a phosphate prodrug strategy to facilitate formulation and improve oral bioavailability.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19410458     DOI： 10.1016/j.bmcl.2009.04.030

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

1.  The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.

Authors:  Haihao Zhu; Steve Woolfenden; Roderick T Bronson; Zahara M Jaffer; Sofia Barluenga; Nicolas Winssinger; Allan E Rubenstein; Ruihong Chen; Al Charest
Journal:  Mol Cancer Ther       Date:  2010-07-19       Impact factor: 6.261

2.  Insights into radicicol biosynthesis via heterologous synthesis of intermediates and analogs.

Authors:  Hui Zhou; Kangjian Qiao; Zhizeng Gao; John C Vederas; Yi Tang
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

3.  A novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo.

Authors:  Jieun R C Cha; Kyle J H St Louis; Miranda L Tradewell; Benoit J Gentil; Sandra Minotti; Zahara M Jaffer; Ruihong Chen; Allan E Rubenstein; Heather D Durham
Journal:  Cell Stress Chaperones       Date:  2013-10-03       Impact factor: 3.667

4.  Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Authors:  Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

5.  Inhibition of HSP90 with pochoximes: SAR and structure-based insights.

Authors:  Sofia Barluenga; Jean-Gonzague Fontaine; Cuihua Wang; Kais Aouadi; Ruihong Chen; Kristin Beebe; Len Neckers; Nicolas Winssinger
Journal:  Chembiochem       Date:  2009-11-23       Impact factor: 3.164

6.  The molecular chaperone Hsp90α is required for meiotic progression of spermatocytes beyond pachytene in the mouse.

Authors:  Iwona Grad; Christopher R Cederroth; Joël Walicki; Corinne Grey; Sofia Barluenga; Nicolas Winssinger; Bernard De Massy; Serge Nef; Didier Picard
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

7.  A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.

Authors:  Linda Kinzel; Anne Ernst; Michael Orth; Valerie Albrecht; Roman Hennel; Nikko Brix; Benjamin Frey; Udo S Gaipl; Gabriele Zuchtriegel; Christoph A Reichel; Andreas Blutke; Daniela Schilling; Gabriele Multhoff; Minglun Li; Maximilian Niyazi; Anna A Friedl; Nicolas Winssinger; Claus Belka; Kirsten Lauber
Journal:  Oncotarget       Date:  2016-07-12

8.  A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism.

Authors:  B Wang; Y Liu; L Huang; J Chen; J J Li; R Wang; E Kim; Y Chen; C Justicia; K Sakata; H Chen; A Planas; R S Ostrom; W Li; G Yang; M P McDonald; R Chen; D H Heck; F-F Liao
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.